Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
SN
Syndax Pharmaceuticals, Inc.
SNDX
Mkt Cap
$1.15B
Volume
2.41M
Next Earnings
November 2nd
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
SN
SNDX
SN
Syndax Pharmaceuticals, Inc.
SNDX
News
·
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal
Mkt Cap
$1.22B
Volume
2.41M
Next Earnings
November 2nd
Chart
Financials
Earnings
News
About
Insider
Filings
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal
Syndax Pharmaceuticals (SNDX) shares fell 15.7% after its phase II MAXPIRe study of axatilimab failed to meet the primary endpoint in idiopathic pulmonary fibrosis (IPF) treatment. The drug showed no benefit in slowing FVC decline, though it maintained a favorable safety profile. The company is discontinuing IPF development but will continue pursuing axatilimab in chronic graft-versus-host disease (cGVHD) with results expected in 2026 and 2028.
Zacks Investment Research · Oct 14, 2026
Syndax Announces Participation in Upcoming Investor Conferences
Syndax Pharmaceuticals announced that CEO Michael A. Metzger and management team will participate in three major investor conferences in May-June 2026: TD Cowen 7th Annual Oncology Innovation Summit (May 27), Jefferies Global Healthcare Conference (June 4), and Goldman Sachs 47th Annual Global Healthcare Conference (June 8). Live webcasts will be available on the company's website.
GlobeNewswire Inc. · May 20, 2026
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment
Sphera Funds Management Ltd. invested $6.54 million in Syndax Pharmaceuticals by purchasing 374,847 shares in Q4 2025. Syndax has demonstrated strong commercial traction with two approved therapies generating $172.4 million in annual revenue, up significantly from $23.7 million the prior year. The stock has surged over 80% in the past year, reflecting accelerating adoption of its oncology treatments.
The Motley Fool · Mar 13, 2026
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
Syndax Pharmaceuticals and the World Orphan Drug Alliance announced a collaboration to expand access to Revuforj (revumenib), a first-in-class menin inhibitor, through a Managed Access Program in regions including parts of Eurasia, Central and Southeast Europe, Israel, the Middle East, Turkey, Latin America, and Africa where the drug is not yet commercially available.
GlobeNewswire Inc. · Jan 7, 2026
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
Syndax Pharmaceuticals' CEO will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference, discussing the company's innovative cancer therapies and pipeline developments.
GlobeNewswire Inc. · Dec 1, 2025
Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
The FDA approved Revuforj (revumenib) for treating relapsed or refractory acute myeloid leukemia with NPM1 mutation in adult and pediatric patients, marking the first and only therapy approved for multiple acute leukemia subtypes.
GlobeNewswire Inc. · Oct 24, 2025
Menin Inhibitors Drug Market Report 2025: Price, Sales & Clinical Trials Insights 2024-2028 - Kura Oncology & Kyowa Kirin Progress with New Drug Applications
Market report highlights emerging menin inhibitor drugs targeting high-risk acute leukemias, with over 15 drugs in clinical trials and potential market opportunity exceeding $400 million by 2028.
GlobeNewswire Inc. · Oct 10, 2025
Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025
Syndax Pharmaceuticals will report its Q2 2025 financial results and host a conference call on August 4, 2025, providing an update on its innovative cancer therapies and ongoing clinical trials.
GlobeNewswire Inc. · Jul 28, 2025
Syndax Announces Participation in June Investor Conferences
Syndax Pharmaceuticals announced that it will present data on its cancer therapies Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) at the upcoming EHA 2025 conference.
GlobeNewswire Inc. · May 29, 2025
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Syndax Pharmaceuticals reported strong initial sales of its cancer drug Revuforj and launched its chronic GVHD drug Niktimvo in the U.S. The company expects to submit a supplemental NDA for Revuforj in relapsed/refractory mNPM1 AML in 2Q25 and has a robust development strategy underway for both drugs.
GlobeNewswire Inc. · Mar 3, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
SN
SNDX
Syndax Pharmaceuticals, Inc.
Buy
Sell
Market
Limit
Soon
SNDX
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any SNDX yet.
Related Tickers
Earnings